Omega Healthcare Investors (OHI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 6, 2025, with four key proposals: election of eight directors, ratification of Ernst & Young LLP as auditor, advisory vote on executive compensation, and approval to amend the charter to increase authorized common stock shares from 350M to 700M.
The board recommends voting in favor of all proposals, emphasizing the importance of additional authorized shares for investment flexibility and growth.
The company outperformed key REIT indices in total shareholder return over 1-, 3-, 5-, and 10-year periods, maintained a $0.67/share quarterly dividend, and executed $1.1B in new investments in 2024.
Voting matters and shareholder proposals
Proposals include electing eight incumbent directors, ratifying Ernst & Young LLP as auditor, advisory approval of executive compensation, and amending the charter to increase authorized shares.
The board unanimously recommends voting FOR all proposals.
Shareholders can vote online, by phone, mail, or during the virtual meeting.
Board of directors and corporate governance
The board consists of eight directors, seven of whom are independent; roles of Chair and CEO are separated.
Directors bring diverse skills in leadership, accounting, real estate, healthcare, investment, and sustainability; 38% are women and two bring racial diversity.
Annual election of directors, majority voting standard, proxy access, and regular board evaluations are in place.
Committees include Audit, Compensation, Nominating & Corporate Governance, and Investment, all with independent members.
Latest events from Omega Healthcare Investors
- Strong 2025 results and 2026 outlook driven by higher earnings, investments, and portfolio strength.OHI
Q4 20255 Feb 2026 - Consistent high-yield growth, strong financials, and demographic tailwinds drive expansion.OHI
Investor presentation5 Feb 2026 - Q2 net income and FFO rose, AFFO guidance increased, but operator and regulatory risks remain.OHI
Q2 20242 Feb 2026 - Q3 FAD and net income rose, AFFO guidance raised, but operator and regulatory risks persist.OHI
Q3 202417 Jan 2026 - Q4 delivered strong growth, decade-low leverage, and a robust 2025 outlook with U.K. investments.OHI
Q4 20248 Jan 2026 - Q1 2025 net income and AFFO rose sharply, driving higher guidance and robust investments.OHI
Q1 202525 Dec 2025 - Board recommends FOR all proposals, citing strong performance and enhanced ESG focus.OHI
Proxy Filing1 Dec 2025 - Shareholders will vote on more authorized shares, auditor ratification, and allow brokers discretionary voting.OHI
Proxy Filing1 Dec 2025 - Q3 2025 delivered higher earnings, raised guidance, and strong investment-driven growth.OHI
Q3 20251 Nov 2025